LONDON, June 2 (Reuters) - GlaxoSmithKline said onThursday it now expects to file its new three-in-one inhaledlung drug for U.S. approval by the end of 2016, rather than thefirst half of 2018 as previously expected, in a boost for itspivotal respiratory business.
The so-called "closed triple", a once-daily drug beingdeveloped with Innoviva, combines fluticasone,umeclidinium and vilanterol in a single inhaler for patientswith chronic obstructive pulmonary disease.
(Reporting by Ben Hirschler; editing by Jason Neely)